785 related articles for article (PubMed ID: 24239116)
1. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Nakagawa I; Park HS; Wada T; Yokoyama S; Yamada S; Motoyama Y; Kichikawa K; Nakase H
Neurol Res; 2017 Aug; 39(8):695-701. PubMed ID: 28290236
[TBL] [Abstract][Full Text] [Related]
3. Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
Nakagawa I; Park HS; Yokoyama S; Wada T; Hironaka Y; Motoyama Y; Takayama K; Kichikawa K; Nakase H
J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):163-71. PubMed ID: 26493334
[TBL] [Abstract][Full Text] [Related]
4. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
7. Prospective registry of carotid artery stenting in Japan--investigation on device and antiplatelet for carotid artery stenting.
Sakai N; Yamagami H; Matsubara Y; Ezura M; Hyodo A; Matsumaru Y; Miyachi S; Okada Y; Terada T; Yokoi H; Nakamura M; Matsumoto Y; Sakai C;
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1374-84. PubMed ID: 24534127
[TBL] [Abstract][Full Text] [Related]
8. Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Kono K; Shintani A; Yoshimura R; Okada H; Tanaka Y; Fujimoto T; Tomura N; Terada T
Acta Neurochir (Wien); 2013 Aug; 155(8):1549-57. PubMed ID: 23715948
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol reduces restenosis after carotid artery stenting.
Takigawa T; Matsumaru Y; Hayakawa M; Nemoto S; Matsumura A
J Vasc Surg; 2010 Jan; 51(1):51-6. PubMed ID: 19879096
[TBL] [Abstract][Full Text] [Related]
10. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Lee BK; Lee SW; Park SW; Lee SW; Park DW; Kim YH; Lee CW; Hong MK; Kim JJ; Jang S; Chi HS; Park SJ
Am J Cardiol; 2007 Aug; 100(4):610-4. PubMed ID: 17697815
[TBL] [Abstract][Full Text] [Related]
11. Use of cilostazol in percutaneous coronary interventions.
Rogers KC; Faircloth JM; Finks SW
Ann Pharmacother; 2012 Jun; 46(6):839-50. PubMed ID: 22669796
[TBL] [Abstract][Full Text] [Related]
12. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
13. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
[TBL] [Abstract][Full Text] [Related]
14. Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Alcocer F; Novak Z; Combs BR; Lowman B; Passman MA; Mujib M; Jordan WD
J Vasc Surg; 2014 Apr; 59(4):950-5. PubMed ID: 24491238
[TBL] [Abstract][Full Text] [Related]
15. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
[TBL] [Abstract][Full Text] [Related]
16. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
17. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
[TBL] [Abstract][Full Text] [Related]
18. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.
Lee SP; Suh JW; Park KW; Lee HY; Kang HJ; Koo BK; Chae IH; Choi DJ; Rha SW; Bae JW; Cho MC; Kwon TG; Bae JH; Kim HS;
Trials; 2010 Aug; 11():87. PubMed ID: 20735821
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting.
González A; Moniche F; Cayuela A; Gonzalez-Marcos JR; Mayol A; Montaner J
J Vasc Surg; 2014 Aug; 60(2):428-35. PubMed ID: 24629989
[TBL] [Abstract][Full Text] [Related]
20. Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Jeong YH; Park Y; Kim IS; Yun SE; Kang MK; Hwang SJ; Kwak CH; Hwang JY
Thromb Haemost; 2010 Dec; 104(6):1286-9. PubMed ID: 20838742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
